PharmaGap says PhGalpha1 stable cancer drug

By Elaine Rigoli

Tampa, Fla., Sept. 21 - PharmaGap, Inc. said the results of new animal tests of its lead cancer drug, PhGalpha1, demonstrate the ability of both PhGalpha1 compounds, when administered by way of a recognized clinical therapeutic route, to display sufficient stability to reach the tumor and demonstrate a biological effect.

The Ottawa-based biotechnology company said this confirms that the PharmaGap compounds may be deliverable to select cancers via the intra-peritoneal route, an accepted mode of delivery in the clinic, and as such, represents a significant advance by PharmaGap in the development of a commercializable cancer drug.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.